Tobacco smoking is the most important and well-established bladder cancer risk factor and a rich source of chemical carcinogens and reactive oxygen species that can induce damage to DNA in urothelial cells. Therefore, common variation in DNA repair genes might modify bladder cancer risk. In this study, we present results from meta-analyses and pooled analyses conducted as part of the International Consortium of Bladder Cancer. We included data on 10 single nucleotide polymorphisms corresponding to seven DNA repair genes from 13 studies. Pooled analyses and meta-analyses included 5,282 cases and 5,954 controls of non-Latino white origin. We found evidence for weak but consistent associations with ERCC2 D312N [rs1799793; per-allele odds ratio (OR), 1.10; 95% confidence interval (95% CI), 1.01-1.19; P = 0.021], NBN E185Q (rs1805794; per-allele OR, 1.09; 95% CI, 1.01-1.18; P = 0.028), and XPC A499V (rs2228000; per-allele OR, 1.10; 95% CI, 1.00-1.21; P = 0.044). The association with NBN E185Q was limited to ever smokers (interaction P = 0.002) and was strongest for the highest levels of smoking dose and smoking duration. Overall, our study provides the strongest evidence to date for a role of common variants in DNA repair genes in bladder carcinogenesis. [Cancer Res 2009;69(17):6857-64] 
Introduction
Tobacco smoking is the most important and well-established risk factor for bladder cancer, contributing up to 50% of bladder cancer occurrence in men and 20% in women (1) . Another important risk factor is occupational exposures to aromatic amines (2) . A common property of these exposures is the presence of carcinogens that can induce DNA damage in the bladder epithelium. Specifically, tobacco smoke is a rich source of polycyclic aromatic hydrocarbons, aromatic amines, heterocyclic amines, and N-nitroso compounds, which can produce DNA bulky adducts that may lead to DNA damage (3) . Aromatic amines have also been identified in hair dyes, and use of these products has been associated with bladder cancer risk in some studies (4) . Tobacco smoke is also a rich source of reactive oxygen species, which can induce damage to DNA (5) and can accumulate in the bladder as a by-product of the metabolism of chemical carcinogens present in tobacco smoke (6) (7) (8) (9) . Genetic risk factors identified thus far include common polymorphisms in xenobiotic metabolism enzymes, such as NAT2 and GSTM1, both of which are involved in the detoxification of arylamines (10, 11) . In addition, GSTM1 participates in the detoxification of reactive oxygen species.
Genotoxic compounds derived from the metabolism of chemical carcinogens can contribute to the accumulation of several forms of DNA damage, such as bulky adducts, single-strand (SSB) and double-strand breaks (DSB), abasic sites, and modified bases. DNA repair mechanisms exist to prevent detrimental consequences of these types of DNA damage. Specifically, base damage, abasic sites, and SSBs are repaired through the base excision repair (BER) pathway, whereas DSBs are repaired by either nonhomologous end joining (NHEJ) or the homologous recombination repair (HRR) pathways. Bulky adducts are generally repaired by the nucleotide excision repair (NER) pathway. Individuals vary in their ability to repair DNA damage, and it has been hypothesized that DNA repair gene polymorphisms may partly explain this variability. In the past decade, several groups have investigated the role of selected DNA repair single nucleotide polymorphisms (SNP) and bladder cancer risk and the potential modifier role of these polymorphisms on the effects of smoking. Whereas some interesting common findings have emerged, larger sample sizes are required to evaluate the associations of these polymorphisms in bladder cancer risk. The role of DNA repair on bladder carcinogenesis is further supported by the finding that reduced DNA repair capacity, as measured in lymphocytes, associated with increased bladder cancer risk (12) .
The International Consortium of Bladder Cancer (ICBC) 31 was formed in 2005 to facilitate the pooling of comparable data on environmental and genetic risk factors across studies to overcome the limited statistical power of individual studies. In this report, we present meta-analyses and pooled analyses of published and unpublished data on 10 SNPs corresponding to seven DNA repair genes that play key roles in the NER, BER, HRR, and NHEJ DNA repair pathways. Specifically, we report findings on the associations between bladder cancer risk and each SNP and their interactions with cigarette smoking. These 10 SNPs were selected because each had been previously evaluated in at least three participating studies.
Materials and Methods
We carried out a literature review in January 2008 to identify DNA repair polymorphisms that had been reported by three or more bladder cancer studies. This resulted in the identification of 12 unique polymorphisms. Ten of these SNPs had been evaluated by at least three studies participating in ICBC and are included in this report: rs1799793 ERCC2 D312N ( five studies) and rs13181 K751Q (eight studies), rs2228000 XPC A499V (three studies) and rs2228001 K939Q ( four studies), rs1799782 XRCC1 R194W (seven studies) and rs25487 R399Q (nine studies), rs861539 XRCC3 T241M (eight studies), rs1130409 APEX1 D148E (six studies), rs1805794 NBN E185Q ( five studies), and rs1799801 ERCC4 S835S ( four studies).
Study Subjects
Twelve studies contributed case-control data and one study provided case-only data, to the ICBC, for a total of 6,348 cases and 6,752 controls (Table 1). Supplementary Tables S1 and S2 contain individual data for all contributing studies. Most studies were hospital based, with the exception of three that were population based (LABCS, NHBCS, and SHBCS). We requested data from each study on gender, site of the cancer (urinary bladder, ureter, renal pelvis, or other), age (continuous), race (African descent, Caucasian, Asian, or other non-Caucasian), ethnicity (non-Latino or Latino), case-control status, smoking status (never, current, former), smoking intensity (cigarettes per day), and smoking duration (years of smoking). Most studies reported data on histology (transitional cell carcinoma, in situ carcinoma, adenocarcinoma, or other), and a few reported data on grade using the 2004 WHO grading system (carcinoma of low potential malignancy; Supplementary Table S1 ). For each of the 10 SNPs selected, we were able to include a range of three to nine studies with genotypic data available for each SNPs (Supplementary Table S2 ).
We restricted pooled analyses and meta-analyses to non-Latino whites, who were the predominant racial/ethnic group in 11 of the 12 studies (all minus SHBCS, which included all Chinese). We present results for that study individually. We included all histologic types diagnosed in the urinary bladder. Genotypic, demographic, and smoking data were available from a total of non-Latino 5,282 cases and 5,954 controls that were available for the final pooled and meta-case-control analyses and a total of 5,434 cases that were available for pooled case-only analyses. Most studies had previously published on the SNPs included in these analyses, with the exception of six studies that also contributed unpublished data (EEBCS, FBCS, HBCS, LBCS, UCLABCS, and LABCS).
Genotyping Data
The genotypes contributed for these pooled analyses and meta-analyses were obtained using a variety of techniques, which included PCR-RFLP assays (BBCS, HBCS, NCBCS, NHBCS, SSBCS, and TBCS), Taqman assays (FBCS, HBCS, LABCS, LBCS, NHBCS, SBCS, SHBCS, SSBCS, and TBCS), Golden Gate assays (FBCS), SNP mass-tagging systems (NHBCS and TBCS), direct sequencing (FBCS), primer extension-denaturing high-performance liquid chromatography (NHBCS and TBCS), and SNPlex (UCLABCS). Overall, all studies included a 3% to 10% duplicated samples to check for concordance, with the exception of one study that did not include duplicates (BBCS). Further details on the methods used by each study can be found in the references listed in Table 1 , with the exception of studies that contributed unpublished data.
Statistical Analyses
Pooled analyses. We checked among controls for differences between the observed genotypic frequencies and those expected under HardyWeinberg equilibrium (HWE) using m 2 tests. We found no statistically significant deviations from HWE among controls, with the exception of three SNPs from one single study (NHBCS: rs1799793, P = 0.023; rs1799782, P = 0.011; and rs25487, P = 0.002). Analyses excluding this study did not substantially change estimates of association.
For each individual SNP, we present genotype frequencies and estimated odds ratios (OR) and 95% confidence intervals (95% CI) obtained from logistic regression models adjusting for gender, age (at diagnosis for cases and at interview for controls) in 5-y categories, study, and smoking status (never, former, and current). Most studies matched controls to cases on gender and age using 3-to 5-y (BBCS, FBCS, HBCS, SBCS, and TBCS) or 10-y intervals (EEBCS, NCBCS, and NCBCS) or other intervals (LBCS). A few studies also matched on ethnicity (SBCS, HBCS, and LASBCS) and/or hospital/region/neighborhood (SBCS, LASBCS, BBCS, and TBCS). Studies defined ever smoker as those that smoked z1 cigarette/day for at least 1 y (BBCS, FBCS, and LBCS), >100 cigarettes during lifetime (EEBCS, HBCS, LASBCS, NHBCS, SBCS, and UCLABCS), and z1 cigarette/day for at least 6 mo (NCBCS). Most studies defined former smokers as those that quit smoking at least 12 mo before diagnosis. We estimated per-allele ORs (95% CIs) assuming a log-additive mode of inheritance. We note that two studies individually matched cases to controls (LABCS and SBCS). Analyses within these two studies comparing results from conditional logistic models using matched pairs with unconditional logistic regression adjusting for gender, age (at diagnosis for cases and at interview for controls) in 5-y categories, and smoking status (never, former, and current) yielded almost identical results; therefore, matched case-control pairs were broken in final analyses.
Gene-gene and gene-smoking interactions were evaluated by introducing interaction terms in logistic regression models that assumed a log-additive mode of inheritance for the genotype effects. For the case-only analyses to determine the effects of genotype among cases, we used a logistic regression model with smoking as the outcome variable (never/ever status) adjusting for gender, age, and study. We evaluated the independence assumption of genotype and smoking among controls using a logistic regression model with smoking status (never/ever) as the outcome variable and the SNP as the explanatory term adjusting for study, gender, and age. We assessed heterogeneity of relative risk estimates across different studies using logistic models introducing an interaction term. There was no evidence of heterogeneity for any of the SNPs. All tests were two sided, and all analyses were done using the statistical software STATA version 9.2 (STATA Corp.). Haplotype frequencies for ERCC2 were estimated using HaploStats (version 1.2.1) 32 using the statistical program R. 33 Meta-analyses. Meta-analysis was performed to summarize our findings along with previously published studies for the association between the ERCC2 K751Q and D312N, NBN E185Q, and XPC A499V and bladder cancer risk. Counts for the genotypes for Caucasian individuals were used with the same exclusions used for the pooled analyses. In addition, peer-reviewed studies published by January 1, 2009 in English were identified using a PubMed search ''bladder cancer polymorphisms'' and ''bladder cancer risk variants.'' Data on genotype frequencies for cases and controls were obtained from published manuscripts. A random-effect model was used to estimate summary ORs and 95% CIs by weighing each study result by a factor accounting for within-and between-study variance (13) .
False-positive report probability. We used false-positive report probability (FPRP) calculations to evaluate the robustness of statistically significant (P < 0.05) findings as described by Wacholder and colleagues (14) . As previously suggested, a cutoff value of 0.2 was used to denote a ''noteworthy finding, '' with values of <0.2 indicating a robust association for a given prior probability. Statistical power and FPRP were computed by the Excel spreadsheet provided by Wacholder and colleagues using a range of prior probabilities from 0.25 to 0.001 and per-allele ORs ranging from 1.10 to 1.30. The lower bound of prior probabilities was chosen based on Thomas and Clayton (15, 16) . The range of underlying ORs was based on the observed per-allele OR for established associations between common polymorphisms and cancer risk. 34 
Results
Pooled analyses of DNA repair SNPs and bladder cancer risk. In Table 2 , we summarize our findings for the pooled analyses of all 10 SNPs for non-Latino white individuals from 11 studies. We present per-allele ORs assuming a log-additive model. Estimates assuming a dominant or recessive model are presented in Supplementary Table S3 . We observed a modest but statistically significant association between the N-allele in ERCC2 D312N and increased bladder cancer risk (OR per risk allele, 1.10; 95% CI, 1.01-1.19; P trend = 0.021). A similar trend was observed for another SNP in ERCC2, K751Q, which is in linkage disequilibrium with D312N (D ¶ = 0.80, r 2 = 0.59, according to HapMap CEU population; in our pooled study populations, D ¶ = 0.75, r 2 = 0.52). We explored joint effects between the two SNPs by estimating the prevalence of the four possible haplotypes and testing for genotype interactions. We observed no consistent interactions between the two SNPs across studies, although analyses by study suggested an inverse interaction in only two studies (HBCS and NHBCS). The association of each SNP with bladder cancer risk when adjusting for each other was OR = 1.06 (95% CI, 0.95-1.19) and OR = 1.05 (95% CI, 0.94-1.17) for 312N and 751Q alleles, respectively. Assuming a recessive or dominant mode of action did not reveal significant associations that were not captured by the log-additive model (Supplementary  Table S3 ). We also observed a statistically significant association between bladder cancer risk and NBN E185Q, with OR per Q allele of 1.09 (95% CI, 1.01-1.18; P = 0.028), and XPC A499V, with an OR per V allele of 1.10 (95% CI, 1.00-1.21; P trend = 0.044). There was no evidence of a significant association for any of the other seven SNPs or evidence of heterogeneity across studies for any of the SNPs we studied.
Pooled analyses of DNA repair SNPs Â smoking interactions and bladder cancer risk. We observed statistically significant evidence of an interaction between NBN E185Q and measures of cigarette smoking (Table 3) . Specifically, the Q allele was associated with increased bladder cancer risk among ever smokers (OR, 1.17; 95% CI, 1.07-1.28) but did not increase among never smokers (OR, 0.89; 95% CI, 0.77-1.06; P for interaction = 0.002). The relation between the Q allele and bladder cancer risk in current smokers was comparable with that in former smokers (Table 3 ). However, stratification by smoking intensity suggested that increased bladder cancer risk is strongest for the highest smoking intensity category (>20 cigarettes/day; OR, 1.24; 95% CI, 1.04-1.48; interaction P = 0.016). When considering the effect of smoking on bladder cancer risk taking into account NBN E185Q genotypes, we found that among carriers of the EE genotype who reported smoking more than 20 cigarettes per day we estimated an OR of 2.33 We also conducted case-only analyses of NBN-smoking interactions, which allowed us to include an additional 311 cases from the SSBCS study and thus estimate interaction ORs with slightly larger power. Under the assumption of independence between NBN genotype and smoking in the source population, ORs obtained from a case-only analyses are valid estimates of the interaction ORs (17) . We found no evidence for an association between NBN E185Q and ever smoking among controls, and the case-only estimate perallele interaction OR was 1.23 (95% CI, 1.07-1.41). This interaction OR, albeit smaller, is comparable with the one estimated from casecontrol comparisons (interaction OR, 1.32; 95% CI, 1.11-1.56).
We did not find evidence of an interaction between smoking habits and any of the other nine SNPs (Supplementary Tables S4-S7 ). Although the association between the ERCC2 codon 312N and codon 751K alleles seemed stronger among ever (Supplementary Table S4 ) or former (Supplementary Table S5 ) or low-dose or low smoking duration (Supplementary Tables S6-S7 ), neither of these interactions was statistically significant.
Meta-analyses of DNA repair SNPs and bladder cancer risk. We conducted meta-analyses across all studies that contributed data to the ICBC. To make our analyses more comprehensive, for the four SNPs for which we found a statistically significant association with bladder cancer risk, we also included two studies that also reported results for these SNPs but did not contribute data to the ICBC (18, 19) . Results for these four SNPs are summarized with forest plots in Fig. 1 . The meta-OR for ERCC2 D312N and K751Q was 1.09 (95% CI, 1.01-1.17; P = 0.031) and 1.06 (95% CI, 0.99-1.13; P = 0.084), respectively. The meta-OR for NBN E185Q was 1.09 (95% CI, 1.01-1.17; P = 0.022) and for XPC A499V was 1.09 (95% CI, 1.00-1.20; P = 0.045). Forest plots for all other SNPs are presented in Supplementary Fig. S1 . Overall, there was no statistically significant heterogeneity across studies, as measured by the I 2 statistic. We compared the overall ORs obtained for ERCC2 and NBN SNPs with ORs obtained from data contributed by the SHBCS, which was the only study that contributed data on Asian individuals. The minor allele frequency (MAF) for the two ERCC2 SNPs was significantly lower (0.088 and 0.075 for K751Q and D312N, respectively) than among Caucasians, whereas the MAF observed for the NBN E185Q SNP (0.449) was in the same range. Data on the XPC A499V SNP were unavailable from this study. Among SHBCS subjects, we observed log-additive per-allele ORs for ERCC2 D312N of 0.63 (95% CI, 0.43-0.91; P = 0.013), ERCC2 K751Q of 0.76 (95% CI, 0.55-1.05; P = 0.101), and NBN E185Q of 0.97 (95% CI, 0.82-1.15; P = 0.732; Supplementary Table S8 ). We observed statistically significant heterogeneity between the meta-OR obtained for non-Latino whites and the OR observed for Shanghai Chinese for both SNPs in the ERCC2 gene (interaction P = 0.001 and P = 0.018 for D312N and K751Q, respectively). In contrast, no comparable heterogeneity was observed for NBN E185Q.
In Fig. 2 , we present forest plots for NBN Â smoking status interaction. The meta-OR for NBN E185Q among never smokers was 0.89 (95% CI, 0.76-1.103) and among ever smokers was 1.17 (95% CI, 1.07-1.27). There was no statistically significant In contrast to what we observed for non-Latino white studies, we found no evidence of NBN Â smoking interaction among Shanghai Chinese (data not shown). Interestingly, we found evidence of XRCC3 T241M Â smoking interaction (interaction P = 0.0108 for smoking status, P = 0.041 for smoking duration, and P = 0.004 for smoking intensity).
FPRP calculations. FPRP calculations indicated that the observed associations are noteworthy only for high prior probabilities. Specifically, the most significant association with bladder cancer risk in this report was found for ERCC2 D312N (P = 0.021). FPRP calculations reach the threshold of <0.2 at a prior probability level of 0.25 and statistical power to detect a true per-allele OR of z1.1. At a prior probability of 0.1, FPRP < 0.2 was reached for true per-allele ORs of z1.2. The XPC A499V association reached the threshold of FPRP < 0.2 for priors of 0.25 and true ORs of z1.2. The NBN E185Q association for all subjects did not reach the FPRP threshold of <0.2 for any of the combinations of prior probabilities and ORs. However, the observed estimates in ever smokers only were noteworthy for priors of 0.01 and ORs of z1.2.
Discussion
We report findings from pooled analyses and meta-analyses of 10 DNA repair polymorphisms and bladder cancer risk among studies from the United States and Europe participating in the ICBC, along with a comparison with results from a large study from China. These analyses provide evidence for an association between bladder cancer risk and polymorphisms in three DNA repair genes: ERCC2 (D312N and K751Q), NBN (E185Q), and XPC (A499V). Furthermore, the NBN E185Q polymorphism might modify the association between cigarette smoking and bladder cancer risk.
To our knowledge, there is no available data on the functional consequences of the XPC A499V polymorphism for which we found a positive association with bladder cancer risk. This SNP is in linkage disequilibrium with two other polymorphisms in the 3 ¶-untranslated region of the gene; therefore, any of these, or other linked variants, might be responsible for the observed association (20) . The XPC protein plays a key role in global NER by recognizing the distortion of damaged DNA (21, 22) . This pathway repairs bulky adducts, such as those induced by tobacco chemical carcinogens. Interestingly, emerging evidence suggests an additional role for Figure 1 . Meta-plots for DNA repair SNPs that showed a statistically significant association with bladder cancer risk in pooled analyses. The I 2 statistics provide an estimate of the heterogeneity across studies.
XPC in the removal of oxidative damage (23) (24) (25) . The ERCC2 protein also plays a key role in NER as an ATP-dependent DNA helicase. In our data, two SNPs in the ERCC2 were associated with bladder cancer risk. The ERCC2 D312N, but not K751Q, has been reported to associate with a 2.5-fold increase in UV-induced apoptosis in a lymphoblastoid cell line (26) . The literature for genotype-phenotype association studies for ERCC2 SNPs has been inconsistent, hindering final conclusions about the mechanistic bases for the observed associations between these SNPs and disease, but an etiologic role for D312N seems plausible (27) . Finally, we also report an association with the NBN E185Q polymorphism, which supports the conclusions of a recent overview of previous studies done on DNA repair and bladder cancer risk (28) . The NBN protein is a member of the MRN complex, which participates in DSB detection and signaling (21, 29) . The functional effect of the E185Q variant has not been characterized, although recent studies support an association between this polymorphism and differences in DNA repair outcomes (30, 31) .
Overall, our findings support a role in bladder carcinogenesis for SNPs that play key roles in the repair of bulky adducts (XPC and ERCC2) and oxidative damage (XPC and NBN). Many environmental exposures can contribute to these types of damages. We considered cigarette smoke, which is the strongest risk factor for bladder cancer and contains chemical carcinogens that are known to induce bulky adducts, base damage, and DNA strand breaks in the bladder epithelium. In addition, the metabolism of tobacco carcinogens generates free radicals that can contribute to further oxidative damage. A role of oxidative damage in bladder carcinogenesis is consistent with our finding of an interaction between the NBN E185Q polymorphism and cigarette smoking. Our results indicate that the association between cigarette smoking and bladder cancer risk is stronger among carriers of the NBN codon 185Q allele. Although we observed a stronger association between NBN E185Q and bladder cancer risk among individuals that reported the highest smoking doses or duration, we saw little evidence of a doseresponse trend with increasing dose or duration of smoking. We did not find evidence of differences in associations with bladder cancer risk for ERCC2 or XPC when considering smoking habits. The presence of an association between these SNPs and bladder cancer risk among nonsmokers suggests that there are endogenous or environmental exposures other than smoking that might be important sources of DNA damage in the bladder. Potential candidates include passive smoking, use of hair dyes, occupational exposures, and dietary sources of oxidative damage.
A strength of these analyses is the inclusion of both published and unpublished data from ICBC participating studies, thus minimizing the possibility of publication bias. To minimize confounding by population admixture, we restricted our analyses to non-Latino whites, which represented the majority of subjects included in participating studies. Given that studies were conducted in different populations in the United States and Europe using a variety of study designs, it seems unlikely that any remaining biases would consistently occur in the same direction across studies. Therefore, the consistency of findings across studies indicates that results are unlikely to be driven by biases specific to particular studies.
A comparison of our pooled ORs and meta-ORs to those obtained using data contributed by one large study in Shanghai highlighted interesting differences in estimates for both SNPs in the ERCC2 gene and suggested a role for the XRCC3 M241T SNP as an effect modifier of smoking. Future studies within the ICBC including more Asian populations will allow us to follow up on these findings.
Although the statistical power of the pooled analyses was adequate (>0.80) to detect per-allele ORs of z1.2 for most SNPs evaluated, the power to detect per-allele ORs of f1.1 was more limited. FPRP calculations that take into account power and prior probability of an association to evaluate the robustness of significant findings indicated that the observed associations for ERCC2, XPC, and NBN are noteworthy only for relatively high prior probabilities (>0.01). Given that the knowledge on functional consequences of the identified SNPs is still limited (see discussion above), such high priors are difficult to justify (15, 16) . To our knowledge, this report includes most bladder cancer studies with DNA available to date; therefore, it will take sometime before pooled analyses can include significantly larger number of bladder cancer cases.
Overall, our study indicates that alterations in the NER and DSB repair pathways could be relevant contributors to bladder carcinogenesis. Further studies comprehensively characterizing these pathways and accounting for relevant environmental exposures should offer further insight into the role of DNA repair in bladder cancer. Figure 2 . Meta-plots for NBN E185Q stratified by smoking status (ever versus never). The I 2 statistics provide an estimate of the heterogeneity across studies.
